stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Shares outstanding
GeneDx Holdings Corp.'s shares outstanding at the end of fiscal 2025 was $28.6M, up 6.51% from $26.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $29.7M. Over the past ten years it has ranged from $0.00 (fiscal 2019) to $28.6M (fiscal 2025) — the current reading is the highest in ten years. GeneDx Holdings Corp. ranks 34th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $28.6M | 6.51% |
| FY2024 | $26.9M | 10.61% |
| FY2023 | $24.3M | 137.49% |
| FY2022 | $10.2M | 212.61% |
| FY2021 | $3.3M | 2,106,087.29% |
| FY2020 | $155.48 | — |
| FY2019 | $0.00 | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $29.7M | 1.28% |
| Mar 2026 | $29.3M | 2.42% |
| Dec 2025 | $28.6M | (0.54%) |
| Sep 2025 | $28.8M | (3.21%) |
| 20 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| OPK OPKO Health, Inc. compare | $746.5M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| NEO NeoGenomics, Inc. compare | $128.6M |
| PSNL Personalis, Inc. compare | $107.2M |
| VCYT Veracyte, Inc. compare | $82.8M |
| CDNA CareDx, Inc. compare | $55.0M |
| CSTL Castle Biosciences, Inc. compare | $30.6M |
| WGS GeneDx Holdings Corp. | $29.7M |
| FRNM Freenome, Inc compare | $2.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement